ASGCT highlighted growing clinical and regulatory focus on solving AAV’s “one-and-done” limitation by enabling redosing and addressing pre-existing immunity. BioCentury’s coverage pointed to strategies that would expand the therapeutic window for gene therapy by managing immune responses that can block repeat administration. The emphasis reflects an industry problem: many AAV approaches face challenges when patients need additional dosing for disease progression or durability. While the excerpt is a conference-focused highlight, the topic directly connects to how companies and regulators are thinking about next-generation study designs, patient selection, and immunogenicity management for repeat dosing.